Abstract
RATIONALE: Unlike conventional indices of asthma progression measuring lung function parameters, quality-of-life (QoL) assessments provide data on patients' daily physical, emotional and social difficulties. The effect of ciclesonide (CIC), administered via a hydrofluoroalkane metered-dose inhaler, on QoL was evaluated in a combined analysis of two identical, Phase III, 12-week, multicenter, double-blind, randomized, parallel-group, placebo (PBO)-controlled trials. QoL was assessed using the Juniper Asthma Quality of Life Questionnaire (AQLQ).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
